首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1566159

癌症藥物市場規模、佔有率、成長分析、按藥物類別、按療法、按適應症、按劑型、按地區 - 產業預測，2024-2031 年

Oncology Drugs Market Size, Share, Growth Analysis, By Drug Class, By Therapy, By Indication, By Dosage Form, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月05日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球抗癌藥物市場規模為1,190億美元，從2023年的1,336.4億美元成長到2031年的3,380.4億美元，預計在預測期內（2024-2031年）成長。 %。

全球抗癌藥物市場是製藥業快速發展的重要組成部分。癌症藥物通常稱為抗癌藥物或化療藥物，是專門為診斷、治療和管理各種癌症而開發的。這些藥物對於對抗癌症至關重要，因為它們針對癌細胞並抑制其生長或完全消除它們。由於多種因素，該市場正在經歷顯著成長。受老化、不健康生活方式、環境暴露和遺傳傾向等因素影響，全球癌症發生率不斷上升，推動了對有效治療的需求。此外，醫學研究和技術的進步促進了創新癌症治療方法的發展。研究人員和製藥公司正在不斷探索新的治療方法，包括標靶治療、免疫療法和個人化醫療，有望改善患者的治療結果和存活率。癌症治療藥物市場多種多樣，針對各種癌症類型的藥物種類繁多，包括肺癌、乳腺癌、結直腸癌和前列腺癌，有口服、注射和靜脈注射形式出售。該領域競爭激烈，各大製藥公司在研究、臨床試驗、監管核准和行銷方面投入巨資，以將新產品推向市場。總體而言，在對抗癌症和改善患者治療效果的持續需求的推動下，癌症治療市場對於製藥業來說是一個充滿活力且至關重要的領域。持續的投資、研究和合作對於應對癌症不斷變化的挑戰和滿足世界對有效治療方法的需求至關重要。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

F. Hoffmann-La Roche Ltd.（Switzerland）
Amgen（US）
Novartis AG（Switzerland）
Bristol-Myers Squibb Company（US）
Pfizer Inc.（US）
Astellas Pharma Inc.（Japan）
Johnson & Johnson（US）
AstraZeneca plc（UK）
AbbVie Inc.（US）
Merck & Co., Inc.（US）
Eli Lilly and Company（US）
Sanofi SA（France）
Gilead Sciences, Inc.（US）
Regeneron Pharmaceuticals, Inc.（US）
Incyte Corporation（US）
Vertex Pharmaceuticals Incorporated（US）
Seagen Inc.（US）
Blueprint Medicines Corporation（US）
Mirati Therapeutics, Inc.（US）
Xencor, Inc.（US）
NantKwest, Inc.（US）
Zymeworks Inc.（Canada）
Karyopharm Therapeutics Inc.（US）
Exelixis, Inc.（US）

簡介目錄

Product Code: SQMIG35J2087

Global Oncology Drugs Market size was valued at USD 119 billion in 2022 and is poised to grow from USD 133.64 billion in 2023 to USD 338.04 billion by 2031, growing at a CAGR of 12.3% during the forecast period (2024-2031).

The global oncology drug market is a rapidly advancing and crucial segment of the pharmaceutical industry. Oncology drugs, commonly referred to as anticancer or chemotherapy drugs, are specifically developed to diagnose, treat, and manage various types of cancer. These medications are essential in the fight against cancer, as they target and inhibit the growth of cancer cells or eliminate them entirely. The market has experienced significant growth due to several contributing factors. The rising incidence of cancer globally has driven up the demand for effective treatments, influenced by factors such as an aging population, unhealthy lifestyles, environmental exposures, and genetic predispositions. Additionally, advancements in medical research and technology have led to the development of innovative oncology therapies. Researchers and pharmaceutical companies are continuously exploring new treatment options, including targeted therapies, immunotherapies, and personalized medicine, which have demonstrated promising improvements in patient outcomes and survival rates. The oncology drug market is diverse, with a broad range of medications aimed at different cancer types, such as lung, breast, colorectal, and prostate cancers, available in forms like oral pills, injectables, and intravenous infusions. This sector is highly competitive, with major pharmaceutical companies investing heavily in research, clinical trials, regulatory approvals, and marketing to bring new products to market. Overall, the oncology drug market is a dynamic and essential area of the pharmaceutical industry, driven by the ongoing need to combat cancer and enhance patient outcomes. Continued investment, research, and collaboration are vital to addressing the evolving challenges of cancer and meeting the global demand for effective treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Drugs Market Segmental Analysis

Global Oncology Drugs Market is segmented by Drug Class, Therapy, Indication, Dosage Form, Distribution Channel, and Region. Based on Drug Class, the market is segmented into Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others. Based on Therapy, the market is segmented into Chemotherapy, Targeted Therapy, and Immunotherapy. Based on Indication, the market is segmented into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others. Based on Dosage Form, the market is segmented into Solid, Liquid, Injectable, and Other. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Oncology Drugs Market

The rising global incidence of cancer is a major factor propelling the growth of the oncology drug market. Contributing factors include aging populations, changes in lifestyle, and environmental influences, all of which increase the overall burden of cancer. This heightened demand for effective treatments is consequently driving the need for oncology drugs. As the prevalence of cancer continues to rise, there is an urgent need for advanced and effective treatment options. The growing demand for oncology drugs reflects the necessity to address this expanding health challenge and provide effective solutions to manage and treat various types of cancer.

Restraints in the Global Oncology Drugs Market

One major restraint for the global oncology drugs market is the high cost associated with the development and treatment of cancer drugs. The extensive research, clinical trials, and regulatory approvals required for oncology drugs often result in significant expenses. These high costs can limit patient access to these treatments and pose financial challenges for healthcare systems and insurance providers. Additionally, the expense of cancer medications may hinder the market's growth, particularly in regions with limited healthcare budgets or in lower-income populations.

Market Trends of the Global Oncology Drugs Market

Targeted therapies have become a prominent trend in the development of oncology drugs. These treatments are engineered to precisely target cancer cells or their specific genetic mutations, thereby limiting harm to healthy cells. This focused approach has demonstrated significant potential in enhancing treatment outcomes and minimizing side effects. The advancement of targeted therapies represents a major shift in oncology, offering more effective and personalized treatment options. By concentrating on the unique characteristics of cancer cells, these therapies have shown promising improvements in patient outcomes and have contributed to a reduction in adverse effects commonly associated with traditional treatments.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Oncology Drugs Market by Drug Class

Market Overview
Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
Targeted Drugs
- Monoclonal Antibodies
- Others
Hormonal Drugs
Others

Oncology Drugs Market by Therapy

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy

Oncology Drugs Market by Indication

Market Overview
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Others

Oncology Drugs Market by Dosage Form

Market Overview
Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled Syringes
- Others

Oncology Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Oncology Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Seagen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blueprint Medicines Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mirati Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xencor, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NantKwest, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Karyopharm Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exelixis, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments